Invesco Ltd. Tricida, Inc. Transaction History

Invesco Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.14 - $12.49 $197 - $17,610	-1,410 Reduced 9.85%	12,907 $1,000
Q3 2022 Nov 14, 2022	SELL	$8.51 - $13.6 $1.44 Million - $2.3 Million	-168,954 Reduced 92.19%	14,317 $150,000
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $1.34 Million - $2.17 Million	183,271 New	183,271 $1.77 Million
Q1 2022 May 16, 2022	SELL	$7.35 - $10.63 $1.42 Million - $2.06 Million	-193,858 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $812,265 - $1.85 Million	193,858 New	193,858 $1.85 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.